Vivos Inc (RDGL)

[Musical Shares]

I always get a smile when I know I write something and the "company" who is obviously reading the board decides to write a PR explaining exactly what I brought up 2 days ago.

Of course, it's just a "coincidence" that after a year that they would mention their "clinical patients" TWO days after I kept pressing about it, right?

As usual, the "shareholder" base is congratulating the company for putting out a generic, worthless PR.

And as usual, nobody actually reads what is being wrote. If there was ever a post about "giving information without telling the whole story" this would be it!

Several patients have now completed their one-year follow-up examinations and continue to show no reported adverse effects at these timepoints.

What's "several?" Two? Three? Four? What happened to the others? They show no signs of adverse effects but what about complete tumor ablation? Gotta' love the way it's phrased!

Preliminary observations from the treated patients have included instances of tumor size reduction observed over short intervals, with no recurrence noted in those specific cases during the available follow-up period.

Have included instances? Specific cases? How long is available follow-up period? Sounds like only a few really were "successful."

We continue to work toward anticipated DCGI regulatory clearance later this quarter to proceed with an expanded phase of therapy. This next stage would incorporate an enhanced protocol that includes elements suggested during prior FDA interactions, such as whole-body PET examinations, and would focus on treatment of cancerous lymph nodes throughout the body. We will provide an update to our IDE submission soon, incorporating relevant data from these ongoing demonstrations to further support our U.S. regulatory pathway.

They have been talking about another phase since February of 2025. Even so, this phase will take a while if it actually happens. I also find it rather odd that the FDA is requesting for whole-body treatment of cancerous lymph nodes where the indication was only for papillary thyroid cancer. Something seems off here.

It's probably why the FDA rejected it with all the data.

You all are being strung along.